Finished product reference
Calcium Gluconate
Injection · Parenteral · 10 % · 10 mL
- List code
- 200
- Pharmacologic class
- Electrolyte replenisher (calcium salt)
What it is and how it works
Calcium gluconate provides ionised calcium, which is essential for neuromuscular excitability, cardiac conduction and contractility, and coagulation. In hyperkalaemia, calcium antagonises the membrane effects of potassium on the myocardium without lowering serum potassium.
Indications
Acute symptomatic hypocalcaemia (e.g. tetany); cardioprotection in severe hyperkalaemia; hypermagnesaemia and magnesium toxicity; calcium-channel blocker overdose (adjunct).
Dosage and administration (summary)
Adults: 10–20 mL of 10% solution (approximately 2.25–4.5 mmol calcium) by slow intravenous injection over at least 5–10 minutes with ECG monitoring, repeated as necessary or followed by continuous infusion according to serum calcium.
Contraindications
Hypercalcaemia; hypercalciuria; severe renal impairment with calcium stones; concomitant intravenous ceftriaxone in neonates; digitalis toxicity (relative).
Warnings and precautions
Rapid injection may cause bradycardia, arrhythmias, vasodilatation and hypotension; use with extreme caution in patients taking cardiac glycosides. Extravasation can cause tissue necrosis and calcinosis. Do not mix with bicarbonate, phosphate or sulfate solutions (precipitation); products in glass containers are not recommended for repeated or prolonged use in children or patients with renal impairment because of aluminium exposure.
Pregnancy
May be used in pregnancy when indicated.
Storage and supply
Store below 25 °C; do not refrigerate or freeze; do not use if crystals are present.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.